Latest News
AmpliTech Soars on 5G Hardware Certification for North America
AmpliTech shares surged 14% premarket after U.S. and Canadian certification cleared its indoor 5G DAS for immediate sales. The company has orders from a North American mobile operator.
Intuit Q3 Earnings: AI Strategy Under Scrutiny as Stock Plunges 39%
Intuit reports fiscal Q3 results Wednesday, with shares down 39% over the past year. Analysts expect earnings of $12.57 per share on $8.54 billion revenue.
AWS AI Revenue Hits $15B Run Rate as Amazon Ramps Up $200B Infrastructure Spend
Amazon Web Services AI services hit $15B annualized revenue, CEO Andy Jassy says. Amazon plans $200B in AI infrastructure capex for 2026, targeting $600B in AWS sales by 2036.
NextNRG Shares Retreat After Doubling on Record April Sales
NextNRG Inc. shares retreated in premarket after doubling on record April revenue of $9.4 million, as cash concerns and Nasdaq listing pressure weighed on investor sentiment.
GCL Global Shares Surge on $10M ADATA Investment, Nasdaq Compliance Looms
GCL Global Holdings shares surged after ADATA invested $10M in its 4Divinity unit, but the stock still trades below Nasdaq's $1 minimum bid price, facing a Sept. 14 deadline.
Analog Devices Reports Record Quarter, Acquires Empower for $1.5B
Analog Devices beat Q2 estimates with 37% revenue growth to $3.62B, forecast Q3 above expectations, and announced a $1.5B cash acquisition of Empower Semiconductor to boost AI power delivery capabilities.
Hasbro Beats Q1 Estimates on Magic: The Gathering Strength
Hasbro reported Q1 revenue of $1 billion and adjusted EPS of $1.47, both above forecasts. Magic: The Gathering fueled a 26% rise in Wizards and Digital Gaming revenue.
VF Corp Shares Surge on First Revenue Growth in Three Years
VF Corp posted its first annual revenue increase in three years, with Q4 sales topping expectations. Shares jumped 8.2% premarket after the company issued fiscal 2027 guidance.
Lowe's Beats Q1 Estimates but Shares Slip on Housing Headwinds
Lowe's beat Q1 estimates with sales of $23.08B and adjusted EPS of $3.03, but shares fell 3% premarket as rising mortgage rates and weak housing trends weighed on sentiment.
Silexion Advances Pancreatic Cancer Trial Amid Cash Concerns
Silexion Therapeutics progresses its SIL204 pancreatic cancer drug into clinical trials, but a shrinking cash position and recent stock decline highlight funding challenges.
CAVA Surges on Strong Traffic, Q1 Beat, and Raised Outlook
CAVA Group shares surged 6.9% in premarket trade Wednesday after the chain reported a 9.7% increase in same-restaurant sales and beat first-quarter earnings and revenue estimates.